rs397515742
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_000116.5(TAFAZZIN):c.371-13C>G variant causes a splice polypyrimidine tract, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000954 in 1,048,184 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000116.5 splice_polypyrimidine_tract, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TAFAZZIN | NM_000116.5 | c.371-13C>G | splice_polypyrimidine_tract_variant, intron_variant | ENST00000601016.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TAFAZZIN | ENST00000601016.6 | c.371-13C>G | splice_polypyrimidine_tract_variant, intron_variant | 1 | NM_000116.5 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome AF: 9.54e-7 AC: 1AN: 1048184Hom.: 0 Cov.: 23 AF XY: 0.00 AC XY: 0AN XY: 324440
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 09, 2011 | The 371-13C>T variant (TAZ) has not been previously reported nor previously iden tified by our laboratory. This variant is located in the 3' splice consensus seq uence, but does not alter the invariant -1/-2 positions. Splicing computational tools do not predict altered splicing, though the accuracy of these tools is unk nown. Additional information is needed to assess the clinical significance of th is variant. - |
3-Methylglutaconic aciduria type 2 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 06, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at